T2265

Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.

CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis.

CGP 54626 hydrochloride is a GABAB receptor antagonist.

Positive allosteric modulator of GABAB receptors

5-HT1B full agonist

CGS 20625 is an orally active, specific, and potent partial agonist at the central benzodiazepine receptor with anxiolytic and anticonvulsant activity.CGS 20625 inhibits the binding of [3H]-flunitrazepam to the central benzodiazepine receptor and can be used in studies of neurological disorders such as anxiety and epilepsy.

endothelin-converting enzyme (ECE) inhibitor

Laduviglusib trihydrochloride (CT99021 trihydrochloride) is a selective glycogen synthase kinase 3 (GSK-3) inhibitor with IC50s of 10 nM and 6.7 nM for GSK-3α and GSK-3β. Laduviglusib trihydrochloride inhibits human GSK-3β with a Ki of 9.8 nM. Laduviglusib trihydrochloride is an activator of Wnt/β-catenin signaling. Laduviglusib trihydrochloride induces autophagy.

Chlorisondamine diiodide is a selective nicotinic acetylcholine receptor (nAChR) antagonist and ganglionic blocker that persistently antagonizes partial central effects of nicotine, such as synaptic dopamine release and taste aversion.